Threat to Cefixime Treatment for Gonorrhea by Yokoi, Shigeaki et al.
LETTERS
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 8, August 2007  1275 
increase SLE incidence in Louisiana, 
and if it did increase incidence in Mis-
sissippi, the increase was minimal.
In both 2003 and 2004, Louisi-
ana’s median reporting time to Ar-
boNET was ≈30 days. In 2005, the 
median reporting time prehurricane 
was 36 days and posthurricane was 69 
days. Louisiana state ofﬁ  cials believed 
that this reporting lag was largely due 
to impaired transport and collection 
of biologic samples and relocation 
of diagnostic facilities immediately 
following the hurricane. In contrast, 
in 2003 and 2004, Mississippi’s me-
dian reporting time to ArboNET was 
21 days and 36 days, respectively. In 
2005, the median reporting time pre-
hurricane was 23 days and posthur-
ricane was 14 days. Mississippi state 
ofﬁ   cials believed that the improved 
reporting time was due to the addi-
tional help and longer hours worked 
by health department ofﬁ  cials follow-
ing the hurricane. 
Although Hurricane Katrina dis-
rupted WNV surveillance in Louisi-
ana, it did not appear to increase the 
incidence of WNND and SLE in either 
Louisiana or Mississippi. In coastal 
areas, the hurricane destroyed hous-
ing and impeded vector control, thus 
possibly increasing the risk of mos-
quito-borne infections (1,2). However, 
hurricane-force winds and heavy ﬂ  ood-
ing might have actually decreased the 
risk of WNV and SLE transmission 
by dispersing or killing birds and mos-
quitoes, and destroying their habitat. 
Many people were promptly evacuated 
to less affected areas, where, on the ba-
sis of previous years’ data showing sea-
sonality of WNV transmission, the risk 
of infection was probably decreasing. 
Natural disasters do not usually cause 
an immediate increase in arboviral 
diseases (1,2). However, if hurricanes 
strike early in transmission season, 
there could be a late increase in risk 
after vector and host populations are 
re-established. In addition, risk could 
increase when people are relocated to 
areas where transmission is intense. 
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Threat to Ceﬁ  xime 
Treatment for 
Gonorrhea 
To the Editor: From November 
2002 through May 2003, a total of 4 
Japanese men, ranging in age from 23 
to 45 years, visited the Department of 
Urology at Toyota Memorial Hospital, 
Toyota, Japan. Physical examinations 
showed urethral discharge and dysuria. 
Each had had sexual contact with sex 
workers in central Japan. Four strains 
of Neisseria gonorrhoeae were isolat-
ed from urethral specimens. Treatment 
comprised 200 mg ceﬁ  xime, twice a 
day for 3 days. However, all 4 patients 
returned to the clinic with continuing 
symptoms, despite having completed 
the prescribed course of ceﬁ  xime and 
abstaining from sexual activity. N. 
gonorrhoeae was again isolated from 
urethral swabs. Each patient was then 
treated with 1 g intravenous ceftriax-
one. In the 3 patients who returned to 
the clinic for followup, the ceftriaxone 
treatment resulted in clinical and mi-
crobiologic cure.
Pulsed-ﬁ   eld gel electrophoresis 
(PFGE) analysis of the SpeI-digested 
DNAs of N. gonorrhoeae was per-
formed to assess the relatedness of 
pre- and posttreatment isolates (1). 
For these 8 isolates, MICs of penicil-
lin G, tetracycline, ceﬁ  xime, cefdinir, 
cefodizime, ceftriaxone, levoﬂ  oxacin, 
azithromycin, and spectinomycin were 
determined on chocolate agar (GC) 
medium base supplemented with 1% 
IsoVital X (Becton Dickinson, Frank-
lin Lakes, NJ, USA) and containing 
serial 2-fold dilutions of each agent 
(2). Media were inoculated with 104 
CFU and incubated at 35°C in 5% CO2 
overnight. The MIC was deﬁ  ned as the 
lowest concentration inhibiting growth 
to <1 CFU. β-lactamase activity of 
the isolates was tested with a nitroce-
ﬁ  n disk. The nucleotide sequences of 
the full-length penA gene encoding 
the penicillin-binding protein 2 (PBP 
2) were identiﬁ  ed in the isolates (1). 
Brieﬂ   y, genomic DNAs from each 
isolate were subjected to PCR to am-
plify 3 fragments of the penA gene of 
N. gonorrrhoeae. PCR products were 
sequenced by the dye terminator meth-
od and with an automatic sequencer.
In each of the 4 cases, the PFGE 
patterns of the pre- and posttreatment 
isolates had the same numbers of 
bands (12–16 fragments), and the cor-
responding bands were the same ap-
parent size; the pre- and posttreatment 
isolates were indistinguishable (3). 
MICs of antimicrobial agents for the 
8 isolates are shown in the Table. All 
isolates were enzymatically negative 
for β-lactamase and possessed identi-
cal mosaic alterations in PBP 2. The 
mosaic PBP 2 was composed of frag-
ments of PBP 2 from N. cinerea and 
N. perﬂ  ava and was identical to that 
identiﬁ  ed in our previous study (1).
Until recently, Japanese guide-
lines recommended oral administra-
tion of ceﬁ  xime, 200 mg twice a day LETTERS
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for 3 days to prolong the period of 
time for which the serum drug con-
centration remains above the MIC 
(4). However, treatment failure with 
this ceﬁ  xime regimen was observed in 
our 4 cases of gonorrhea. The isolates 
showed ceﬁ  xime MICs of 0.5–1 μg/
mL and harbored mosaic alterations in 
PBP 2. Most recently, the emergence 
and spread of such strains in Japan 
(1,5,6) have led to the recommenda-
tion that ceftriaxone and spectino-
mycin should be used as the primary 
therapy for gonorrhea instead of oral 
cephalosporins (7).
In 2001, treatment failure was re-
ported in a Caucasian man residing in 
Hawaii who had been given a single 
400-mg dose of ceﬁ  xime for gonorrhea 
(8). Pre- and posttreatment strains of 
N. gonorrhoeae were recovered from 
this patient, and 1 strain was isolated 
from his Japanese female sex partner 
who had visited Hawaii from Japan. 
Another pretreatment strain was iso-
lated from a Micronesian man with 
gonorrhea residing in Hawaii, who had 
had sex with a woman from Malaysia 
or the Marshall Islands. This man was 
successfully treated with a single 400-
mg dose of ceﬁ  xime. For these strains, 
MICs of penicillin, tetracycline, spec-
tinomycin, ceﬁ  xime, ceftriaxone, cip-
roﬂ  oxacin, and azithromycin were 8.0, 
4.0–8.0, <32, 0.25–0.5, 0.125, 8–16, 
and 0.125–0.25 μg/mL, respectively. 
The antibiograms of these strains in 
Hawaii were similar to those of strains 
with mosaic PBP 2 found in our 4 pa-
tients. The introduction to Hawaii of 
such multidrug resistant strains might 
be related to sex partners from Asia. 
Although the strains were not ana-
lyzed for alterations in PBP 2, they 
could have been derived from strains 
with ceﬁ  xime  resistance-associated 
mosaic PBP 2.
The strains with mosaic PBP 2 
showed such decreased susceptibility to 
ceﬁ  xime that they were not effectively 
eradicated by the 3-day treatment. Al-
though it is not clear whether these 
strains are also resistant to the single 
400-mg dose of ceﬁ  xime (8, 9), their 
emergence and spread could threaten 
treatment for gonorrhea with ceﬁ  xime 
(10). Global emergence and spread of 
such multidrug-resistant strains of N. 
gonorrhoeae would be a matter of seri-
ous concern. The antimicrobial suscep-
tibilities of current gonococcal isolates 
must be monitored periodically. In 
particular, posttreatment isolates from 
patients treated unsuccessfully with ce-
ﬁ  xime should be surveyed.
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Table. Antimicrobial drug susceptibilities of clinical isolates of Neisseria gonorrhoeae from patients with gonococcal urethritis treated 
unsuccessfully with a 3-day cefixime regimen* 
MIC (μg/mL) 
Patient Isolate PCG TET CFX CFD CDZ CTX LVF AZM SPC
1 Pre-Tx 4 2 0.5 1 0.125 0.125 16 0.25 16
Post-Tx 4 2 0.5 1 0.125 0.125 16 0.125 32
2 Pre-Tx 8 4 0.5 1 0.25 0.5 8 0.5 32
Post-Tx 8 2 0.5 1 0.125 0.25 8 0.5 16
3 Pre-Tx 4 2 1 2 0.25 0.125 16 0.25 16
Post-Tx 4 2 1 2 0.25 0.125 16 0.25 16
4 Pre-Tx 4 1 1 2 0.25 0.25 16 0.125 16
Post-Tx 4 2 1 2 0.25 0.25 16 0.25 32
*PCG, penicillin G; TET, tetracycline; CFX, cefixime; CFD, cefdinir; CDZ, cefodizime; CTX, ceftriaxone; LVF, levofloxacin; AZM, azithromycin; SPC, 
spectinomycin; Pre-Tx, isolate recovered before cefixime treatment; Post-Tx, isolate recovered after cefixime treatment, i.e., before ceftriaxone treatment. 
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